Prostatic Secretion and Testosterone: Functions, Regulation, and Clinical Relevance
Introduction: The prostate gland produces a fluid that is essential for male fertility, and this production is heavily influenced by the hormone testosterone. Understanding the relationship between prostatic secretion and testosterone is important for men's health, from reproductive function to the diagnosis of prostate diseases. In this three‑chapter article, you will learn: Chapter 1 describes what prostatic secretion is, its normal composition and physiological roles; Chapter 2 explains how testosterone regulates prostate growth and secretion, including the role of dihydrotestosterone (DHT); and Chapter 3 discusses clinical applications such as PSA testing, conditions that affect prostatic fluid, and what is known about testosterone therapy and prostate risk. All information is derived from peer‑reviewed literature and authoritative health organizations.
Chapter 1: Prostatic Secretion – Composition and Functions
The prostate is a small, walnut‑shaped gland located below the urinary bladder in males. Its primary exocrine function is to produce a thin, milky, slightly alkaline fluid that constitutes approximately 20–30% of the total semen volume. This fluid is discharged into the prostatic urethra during ejaculation. Normal prostatic secretion is critical for male fertility because it provides biochemical support to spermatozoa. Without adequate prostatic fluid, sperm motility and survival are compromised. The composition of this fluid is tightly regulated by androgens, primarily testosterone and its more potent metabolite dihydrotestosterone (DHT).
1.1 What Is Prostatic Secretion and What Does It Contain?
Prostatic fluid contains several unique components. It is rich in citric acid, zinc, calcium, and magnesium. It also contains enzymes such as prostatic acid phosphatase (PAP) and prostate‑specific antigen (PSA). PSA is a serine protease responsible for the liquefaction of the seminal coagulum. The fluid’s pH is typically 7.2–7.4, which is slightly alkaline. Zinc ions in prostatic fluid have antimicrobial properties and help stabilize sperm chromatin. The concentration of zinc in prostatic fluid is among the highest in any bodily secretion. These components are produced by the epithelial cells lining the prostatic acini, and their secretion is stimulated by androgenic hormones.
1.2 Role in Semen Liquefaction and Sperm Protection
Immediately after ejaculation, semen forms a gel‑like coagulum due to proteins (semenogelin I and II) from the seminal vesicles. PSA, which is secreted by the prostate, breaks down these gel‑forming proteins, resulting in liquefaction within 5 to 20 minutes. This liquefaction allows sperm to swim freely toward the ovum. Additionally, the alkaline nature of prostatic fluid neutralizes the acidic environment of the vagina (normal vaginal pH is 3.8–4.5), thereby protecting sperm from acid‑induced damage. The high zinc concentration also contributes to antibacterial defense within the male reproductive tract. Any disruption in prostatic secretion—whether due to infection, obstruction, or androgen deficiency—can therefore negatively impact fertility.
- Prostatic fluid contributes ~20‑30% of semen volume.
- Key components: PSA, zinc, citric acid, acid phosphatase.
- Alkaline pH neutralizes vaginal acidity, preserving sperm function.
Chapter 2: Testosterone and Its Regulation of the Prostate
Testosterone is the primary circulating androgen in males, produced mainly by the Leydig cells of the testes. It enters prostate cells by diffusion. Once inside the prostate, the enzyme 5‑alpha‑reductase (type 2 is predominant in the prostate) converts testosterone to dihydrotestosterone (DHT). DHT binds to androgen receptors (AR) in the nucleus of prostatic epithelial and stromal cells with higher affinity than testosterone itself. This binding triggers transcription of androgen‑responsive genes that control cell growth, differentiation, and the production of prostatic secretory proteins (including PSA and PAP). Thus, testosterone indirectly—via DHT—drives prostatic secretion.
2.1 Testosterone Conversion to DHT and Androgen Receptor Signaling
DHT is approximately 2–5 times more potent than testosterone at the androgen receptor. The conversion is irreversible and occurs locally within the prostate. DHT‑AR complexes dimerize and bind to androgen response elements (AREs) on DNA, recruiting co‑activators to initiate transcription of specific genes. Among the most well‑studied androgen‑regulated genes in the prostate are KLK3 (encoding PSA) and ACPP (encoding prostatic acid phosphatase). This signaling cascade is essential for maintaining the secretory phenotype of prostate epithelial cells. Medications called 5‑alpha‑reductase inhibitors (finasteride and dutasteride) block this conversion, leading to reduced intraprostatic DHT levels and decreased PSA secretion, which is used clinically to treat benign prostatic hyperplasia (BPH).
2.2 Effects of Androgen Deprivation on Prostatic Secretion
Clinical and experimental evidence clearly shows that reducing androgen action dramatically decreases prostatic secretion. Men treated with androgen deprivation therapy (ADT) for prostate cancer experience marked atrophy of prostatic epithelial cells, reduced PSA production, and decreased prostatic fluid volume. Similarly, in men with hypogonadism (low serum testosterone), PSA levels are often low, and prostatic fluid volume is diminished. Conversely, testosterone replacement in hypogonadal men restores PSA levels and prostate secretory function. These observations confirm that prostatic secretion is an androgen‑dependent process. However, it is important to note that even with low circulating testosterone, local DHT production in the aging prostate can sometimes maintain secretory activity.
- Testosterone is converted to DHT by 5‑alpha‑reductase in the prostate.
- DHT binds androgen receptors to regulate PSA and prostatic fluid production.
- Androgen deprivation therapy (ADT) reduces prostatic secretion and PSA levels.
Chapter 3: Clinical Perspectives – Diagnostics and Testosterone Therapy
Because prostatic secretion is directly influenced by androgens, measurements of its components—most notably PSA—have become indispensable clinical tools. PSA is produced exclusively by prostatic epithelial cells and is normally present in low concentrations in serum. Elevated serum PSA can indicate prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis. Additionally, the growing use of testosterone replacement therapy (TRT) for symptomatic hypogonadism has raised questions about prostate safety. This chapter reviews current evidence on PSA testing and the relationship between testosterone therapy and prostate health.
3.1 PSA as a Biomarker of Prostatic Secretion
Serum PSA testing is the standard screening tool for prostate cancer, though it is not diagnostic by itself. Normal PSA levels are generally considered below 4.0 ng/mL, but age‑specific and race‑specific adjustments exist. PSA values between 4 and 10 ng/mL are considered “borderline,” and values above 10 ng/mL increase suspicion for malignancy. However, BPH and prostatitis also elevate PSA. Importantly, PSA is a product of prostatic secretion, and factors such as ejaculation, digital rectal exam, and prostate biopsy can transiently raise serum PSA levels. Current guidelines recommend avoiding ejaculation for 24 hours before a PSA test. Despite its limitations, PSA remains the most useful biomarker for prostate cancer detection and monitoring after treatment.
3.2 Testosterone Replacement and Prostate Safety
A historical concern has been that testosterone therapy might stimulate prostate cancer growth. However, large systematic reviews and meta‑analyses have found no increased risk of prostate cancer in hypogonadal men receiving testosterone replacement therapy, provided that men with known or suspected prostate cancer are excluded before treatment. The American Urological Association (AUA) guidelines state that testosterone therapy is not associated with an increased risk of prostate cancer based on current evidence. However, they recommend measuring PSA and performing a digital rectal exam before starting therapy, with follow‑up at 3 to 12 months and then annually. For men with a history of treated prostate cancer, testosterone therapy remains controversial; most guidelines advocate caution. Importantly, testosterone therapy may slightly increase PSA levels within the normal range, but this reflects restoration of normal prostatic function rather than malignancy.
- PSA is an androgen‑regulated protein derived from prostatic secretion.
- Elevated PSA requires further investigation but is not specific for cancer.
- Current evidence shows testosterone therapy does not increase prostate cancer risk in properly screened hypogonadal men.
Conclusion: Prostatic secretion is a complex fluid essential for fertility, and its production is directly regulated by testosterone via conversion to DHT. The relationship between androgens and the prostate has important clinical applications: PSA, a key component of prostatic fluid, serves as a biomarker for prostate disease; and testosterone replacement therapy—when used appropriately—has not been shown to increase prostate cancer risk. Understanding these links helps clinicians and patients make informed decisions about hormone therapy and prostate health monitoring. Always consult a urologist for individual risk assessment.
FAQ
Does low testosterone reduce prostatic fluid volume?
Yes. Men with hypogonadism (clinically low testosterone) often have reduced prostatic secretion and lower PSA levels. Testosterone replacement therapy typically restores PSA and prostatic fluid production. However, other causes such as infection or obstruction should also be considered.
Should I avoid ejaculation before a PSA blood test?
Yes. Many urology guidelines recommend avoiding ejaculation for 24 to 48 hours before a PSA test because ejaculation can temporarily elevate serum PSA levels, potentially leading to false‑positive results. Other activities such as bicycle riding and digital rectal exam should also be avoided before blood draw.
Does testosterone therapy cause prostate cancer?
Current systematic reviews and meta‑analyses show no evidence that testosterone therapy increases the risk of developing prostate cancer in hypogonadal men without pre‑existing prostate cancer. However, it can stimulate the growth of undiagnosed, existing prostate cancer. Therefore, screening with PSA and digital rectal exam is mandatory before starting therapy.
How do finasteride and dutasteride affect prostatic secretion?
Finasteride and dutasteride are 5‑alpha‑reductase inhibitors. They block the conversion of testosterone to DHT in the prostate, leading to reduced DHT levels, decreased prostate epithelial cell activity, lower PSA levels (by about 50%), and reduced prostatic fluid volume. These effects are reversible upon stopping the medication.
References
- StatPearls [Internet]. (2024). Prostate Anatomy. National Library of Medicine.
- Mayo Clinic. (2023). PSA Test – Overview. Mayo Foundation for Medical Education and Research.
- American Urological Association. (2018, amended 2020). Evaluation and Management of Testosterone Deficiency.
- Verze, P., et al. (2011). The role of the prostate in male fertility. Therapeutic Advances in Urology, 3(3), 131-137.
- National Cancer Institute. (2022). Prostate‑Specific Antigen (PSA) Test. NIH.
Comments
Post a Comment